Skip to main navigation Skip to search Skip to main content

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population

  • Antonis C. Antoniou
  • , Xianshu Wang
  • , Zachary S. Fredericksen
  • , Lesley McGuffog
  • , Robert Tarrell
  • , Olga M. Sinilnikova
  • , Sue Healey
  • , Jonathan Morrison
  • , Christiana Kartsonaki
  • , Timothy Lesnick
  • , Maya Ghoussaini
  • , Daniel Barrowdale
  • , Susan Peock
  • , Margaret Cook
  • , Clare Oliver
  • , Debra Frost
  • , Diana Eccles
  • , D. Gareth Evans
  • , Ros Eeles
  • , Louise Izatt
  • Carol Chu, Fiona Douglas, Joan Paterson, Dominique Stoppa-Lyonnet, Claude Houdayer, Sylvie Mazoyer, Sophie Giraud, Christine Lasset, Audrey Remenieras, Olivier Caron, Agnès Hardouin, Pascaline Berthet, Frans B.L. Hogervorst, Matti A. Rookus, Agnes Jager, Ans Van Den Ouweland, Nicoline Hoogerbrugge, Rob B. Van Der Luijt, Hanne Meijers-Heijboer, Encarna B. G'mez García, Peter Devilee, Maaike P.G. Vreeswijk, Jan Lubinski, Anna Jakubowska, Jacek Gronwald, Tomasz Huzarski, Tomasz Byrski, Bohdan G'rski, Cezary Cybulski, Amanda B. Spurdle, Helene Holland, David E. Goldgar, Esther M. John, John L. Hopper, Melissa Southey, Saundra S. Buys, Mary B. Daly, Mary Beth Terry, Rita K. Schmutzler, Barbara Wappenschmidt, Christoph Engel, Alfons Meindl, Sabine Preisler-Adams, Norbert Arnold, Dieter Niederacher, Christian Sutter, Susan M. Domchek, Katherine L. Nathanson, Timothy Rebbeck, Joanne L. Blum, Marion Piedmonte, Gustavo C. Rodriguez, Katie Wakeley, John F. Boggess, Jack Basil, Stephanie V. Blank, Eitan Friedman, Bella Kaufman, Yael Laitman, Roni Milgrom, Irene L. Andrulis, Gord Glendon, Hilmi Ozcelik, Tomas Kirchhoff, Joseph Vijai, Mia M. Gaudet, David Altshuler, Candace Guiducci, Niklas Loman, Katja Harbst, Johanna Rantala, Hans Ehrencrona, Anne Marie Gerdes, Mads Thomassen, Lone Sunde, Paolo Peterlongo, Siranoush Manoukian, Bernardo Bonanni, Alessandra Viel, Paolo Radice, Trinidad Caldes, Miguel De La Hoya, Christian F. Singer, Anneliese Fink-Retter, Mark H. Greene, Phuong L. Mai, Jennifer T. Loud, Lucia Guidugli, Noralane M. Lindor, Thomas V.O. Hansen, Finn C. Nielsen, Ignacio Blanco, Conxi Lazaro, Judy Garber, Susan J. Ramus, Simon A. Gayther, Catherine Phelan, Stephen Narod, Csilla I. Szabo, Javier Benitez, Ana Osorio, Heli Nevanlinna, Tuomas Heikkinen, Maria A. Caligo, Mary S. Beattie, Ute Hamann, Andrew K. Godwin, Marco Montagna, Cinzia Casella, Susan L. Neuhausen, Beth Y. Karlan, Nadine Tung, Amanda E. Toland, Jeffrey Weitzel, Olofunmilayo Olopade, Jacques Simard, Penny Soucy, Wendy S. Rubinstein, Adalgeir Arason, Gad Rennert, Nicholas G. Martin, Grant W. Montgomery, Jenny Chang-Claude, Dieter Flesch-Janys, Hiltrud Brauch, Gianluca Severi, Laura Baglietto, Angela Cox, Simon S. Cross, Penelope Miron, Sue M. Gerty, William Tapper, Drakoulis Yannoukakos, George Fountzilas, Peter A. Fasching, Matthias W. Beckmann, Isabel Dos Santos Silva, Julian Peto, Diether Lambrechts, Robert Paridaens, Thomas Rüdiger, Asta Försti, Robert Winqvist, Katri Pylkäs, Robert B. Diasio, Adam M. Lee, Jeanette Eckel-Passow, Celine Vachon, Fiona Blows, Kristy Driver, Alison Dunning, Paul P.D. Pharoah, Kenneth Offit, V. Shane Pankratz, Hakon Hakonarson, Georgia Chenevix-Trench, Douglas F. Easton, Fergus J. Couch
  • University of Cambridge
  • Mayo Clinic
  • Centre de Recherche en Cancérologie de Lyon
  • Université de Lyon
  • Queensland Institute of Medical Research
  • University Hospital Southampton NHS Foundation Trust
  • Manchester University NHS Foundation Trust
  • Royal Marsden NHS Foundation Trust
  • Guy's and St Thomas' NHS Foundation Trust
  • Yorkshire Regional Genetics Service
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Cambridge University Hospitals NHS Foundation Trust
  • Institut national de la santé et de la recherche médicale
  • Universite Claude Bernard Lyon 1
  • Centre Léon Bérard
  • Université Paris-Sud
  • Georges François Leclerc Cancer Center
  • Netherlands Cancer Institute
  • Erasmus University Rotterdam
  • Radboud University Nijmegen
  • Utrecht University
  • VU University Medical Center
  • Maastricht University
  • Leiden University
  • Pomeranian Medical University in Szczecin
  • University of Utah
  • Stanford University
  • University of Melbourne
  • Columbia University
  • University of Cologne
  • Leipzig University
  • Technical University of Munich
  • University of Münster
  • Kiel University
  • Heinrich Heine University Düsseldorf
  • Heidelberg University 
  • University of Pennsylvania
  • Baylor Health Care System
  • Roswell Park Cancer Institute
  • NorthShore University HealthSystem
  • Tufts University
  • University of North Carolina at Chapel Hill
  • St. Elizabeth Medical Center, Edgewood
  • New York University
  • The Gertner Institute
  • Sheba Medical Center at Tel Hashomer
  • Cancer Care Ontario
  • University of Toronto
  • Memorial Hospital
  • Memorial Sloan-Kettering Cancer Center
  • Yeshiva University
  • Massachusetts Institute of Technology
  • Lund University
  • Karolinska Institutet
  • Uppsala University
  • University of Copenhagen
  • University of Southern Denmark
  • Aarhus University
  • Fondazione IRCCS Istituto Nazionale dei Tumori
  • FIRC Institute of Molecular Oncology
  • IRCCS Istituto Europeo di Oncologia - Milano
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • Hospital Clínico San Carlos de Madrid
  • Medical University of Vienna
  • National Institutes of Health
  • Institute Catala Oncologia
  • Dana-Farber Cancer Institute
  • GENICA
  • University College London
  • University of South Florida
  • MOD SQUAD
  • Biomedical Network on Rare Diseases (CIBERER)
  • Helsinki University Hospital
  • SWE-BRCA
  • University of Pisa
  • University of California at San Francisco
  • German Cancer Research Center
  • Fox Chase Cancer Center
  • IRCCS Istituto Oncologico Veneto - Padova
  • City of Hope National Medical Center
  • Division of Gynecologic Oncology
  • University of California at Los Angeles
  • Beth Israel Deaconess Medical Center
  • Ohio State University
  • University of Chicago
  • Université Laval
  • Landspitali University Hospital
  • Technion-Israel Institute of Technology
  • University of Hamburg
  • Robert Bosch Foundation
  • University of Tübingen
  • Cancer Council Victoria
  • University of Sheffield
  • Demokritos National Centre for Scientific Research
  • Aristotle University of Thessaloniki
  • Hellenic Cooperative Oncology Group
  • Friedrich-Alexander University Erlangen-Nürnberg
  • London School of Hygiene and Tropical Medicine
  • Flanders Institute for Biotechnology
  • KU Leuven
  • Städtischen Klinikum Karlsruhe
  • University of Oulu
  • HEBON
  • Peter Maccallum Cancer Centre
  • The Children's Hospital of Philadelphia

Research output: Contribution to journalArticlepeer-review

277 Scopus citations

Abstract

Germline BRCA1 mutations predispose to breast cancer. To identify genetic modifiers of this risk, we performed a genome-wide association study in 1,193 individuals with BRCA1 mutations who were diagnosed with invasive breast cancer under age 40 and 1,190 BRCA1 carriers without breast cancer diagnosis over age 35. We took forward 96 SNPs for replication in another 5,986 BRCA1 carriers (2,974 individuals with breast cancer and 3,012 unaffected individuals). Five SNPs on 19p13 were associated with breast cancer risk (P trend = 2.3 × 10 9 to P trend = 3.9 × 10 7), two of which showed independent associations (rs8170, hazard ratio (HR) = 1.26, 95% CI 1.17-1.35; rs2363956 HR = 0.84, 95% CI 0.80-0.89). Genotyping these SNPs in 6,800 population-based breast cancer cases and 6,613 controls identified a similar association with estrogen receptor-negative breast cancer (rs2363956 per-allele odds ratio (OR) = 0.83, 95% CI 0.75-0.92, P trend = 0.0003) and an association with estrogen receptor-positive disease in the opposite direction (OR = 1.07, 95% CI 1.01-1.14, P trend = 0.016). The five SNPs were also associated with triple-negative breast cancer in a separate study of 2,301 triple-negative cases and 3,949 controls (Ptrend = 1 × 10 7 to P trend = 8 × 10 5; rs2363956 per-allele OR = 0.80, 95% CI 0.74-0.87, P trend = 1.1 × 10 7).

Original languageEnglish
Pages (from-to)885-892
Number of pages8
JournalNature Genetics
Volume42
Issue number10
DOIs
StatePublished - Sep 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • BRCA1 Protein/genetics
  • Breast Neoplasms/genetics
  • Case-Control Studies
  • Chromosomes, Human, Pair 19/genetics
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Mutation/genetics
  • Polymorphism, Single Nucleotide/genetics
  • Receptor, ErbB-2/genetics
  • Receptors, Estrogen/genetics
  • Receptors, Progesterone/genetics

Fingerprint

Dive into the research topics of 'A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population'. Together they form a unique fingerprint.

Cite this